Dexcom, Inc. share price today

(DXCM)

Dexcom, Inc. share price is $81.01 & ₹6,863.98 as on 5 Dec 2024, 2.30 'hrs' IST

$81.01

▲

0.1

(0.12%)

Market is closed - opens 8 PM, 05 Dec 2024

View live Dexcom, Inc. share price in Dollar and Rupees. Guide to invest in Dexcom, Inc. from India. Also see the sentimental analysis on Indian investors investing in Dexcom, Inc.. Get details on the Indian mutual funds that are investing in Dexcom, Inc.. Get Analyst recommendations and forecasts along with all the Dexcom, Inc.'s financials.

Dexcom, Inc. share price movements

$80.71
$82.17
$81.01
0.37%
Downside
Day's Volatility :1.78%
Upside
1.41%
$62.34
$142.00
$81.01
23.05%
Downside
52 Weeks Volatility :56.1%
Upside
42.95%

Dexcom, Inc. Returns

Period	Dexcom, Inc.	Sector (Health Care)	Index (NASDAQ Composite)
3 Months	14.86%	-4.7%	15.2%
6 Months	-31.21%	0.9%	14.8%
1 Year	-32.75%	11.6%	38.7%
3 Years	-39.51%	12.9%	30.8%

Dexcom, Inc. Key Statistics

in dollars & INR

Previous Close	$80.91
Open	$80.86
Today's High	$82.17
Today's Low	$80.71
Market Capitalization	$31.0B
Today's Volume	$3.2M
52 Week High	$142.0
52 Week Low	$62.34
Revenue TTM	$4.0B
EBITDA	$840.4M
Earnings Per Share (EPS)	$1.65
PE Ratio	48.07
Profit Margin	17.22%
Quarterly Earnings Growth YOY	0.16%
Return On Equity TTM	32.06%

How to invest in Dexcom, Inc. from India?

It is very easy for Indian residents to invest directly in Dexcom, Inc. from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Dexcom, Inc. stock in both rupees (INR) and dollars (USD). Search for Dexcom, Inc. or DXCM on INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Dexcom, Inc. or Rupee/ Dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Dexcom, Inc. shares which would translate to 0.010 fractional shares of Dexcom, Inc. as of today. Learn more about fractional investing here.

Indians via INDmoney can now also, easily transfer and add their money to the US stocks account via INDmoney App. Click here for step by step process for the same

Indian investors sentiment towards Dexcom, Inc.

17.65%

Period: Sep 5, 2024 to Dec 4, 2024. Change in 30 Days versus previous period

Investment in Dexcom, Inc. from India has grown in the last 30 days as on Dec 5, 2024. 17.65% more purchase transactions for Dexcom, Inc. in the last 30 days versus the previous period.

-33%

Period: Sep 5, 2024 to Dec 4, 2024. Change in 30 Days versus previous period

Search volume for Dexcom, Inc. on INDmoney from India has reduced in the last 30 days as on Dec 5, 2024. -33% less investors are searching Dexcom, Inc. in the last 30 days versus the previous period.

Indian Mutual Funds that own Dexcom, Inc.

Name	Shares Held	Change in Shares	% of Assets
ICICI Prudential NASDAQ 100 Index Fund Direct Growth	5192	54.72	0.19%
Motilal Oswal S&P 500 Index Fund Direct Growth	3444	10.99	0.06%

Global Institutional Holdings in Dexcom, Inc.

Vanguard Group Inc
12.14%
BlackRock Inc
8.84%
Capital Research Global Investors
4.60%
State Street Corp
4.27%
Baillie Gifford & Co Limited.
3.84%
Sands Capital Management, LLC
2.64%

Analyst Recommendation on Dexcom, Inc.

Buy

86%Buy

13%Hold

0%Sell

Based on 30 Wall street analysts offering stock ratings for Dexcom, Inc.(by analysts ranked 0 to 5 stars)

Based on 30 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Dexcom, Inc.

What analysts predicted

Upside of 17.59%

Current:

$81.01

Target:

$95.26

Insights on Dexcom, Inc.

Decreasing Revenue
Dexcom, Inc. has experienced a decline in revenue over the last two quarters, dropping from $1.00 billion to $994.2 million. This represents an average decrease of 1.0% per quarter.
Decreasing Net Profit
Dexcom, Inc. has seen a decline in its net profit over the last four quarters, dropping from $256.3 million to $134.6 million. This represents an average decrease of 17.0% in net profit each quarter.
Vs BSX
In the last 1 year, Boston Scientific Corp. has given 64.8% return, outperforming this stock by 97.1%
Vs BSX
In the last 3 years, Boston Scientific Corp. has given 129.2% return, outperforming this stock by 168.1%

Dexcom, Inc. Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$1.0B	↑ 43.58%
Net Income	$-127.1M	↑ 153.19%
Net Profit Margin	-12.32%	↓ 5.33%

	FY19	Y/Y Change
Revenue	$1.5B	↑ 43.08%
Net Income	$101.1M	↓ 179.54%
Net Profit Margin	6.85%	↑ 19.17%

	FY20	Y/Y Change
Revenue	$1.9B	↑ 30.54%
Net Income	$493.6M	↑ 388.23%
Net Profit Margin	25.62%	↑ 18.77%

	FY21	Y/Y Change
Revenue	$2.4B	↑ 27.08%
Net Income	$154.7M	↓ 68.66%
Net Profit Margin	6.32%	↓ 19.3%

	FY22	Y/Y Change
Revenue	$2.9B	↑ 18.84%
Net Income	$341.2M	↑ 120.56%
Net Profit Margin	11.73%	↑ 5.41%

	FY23	Y/Y Change
Revenue	$3.6B	↑ 24.49%
Net Income	$541.5M	↑ 58.7%
Net Profit Margin	14.95%	↑ 3.22%

	Q2 FY23	Q/Q Change
Revenue	$871.3M	↑ 17.51%
Net Income	$115.9M	↑ 138.48%
Net Profit Margin	13.3%	↑ 6.75%

	Q3 FY23	Q/Q Change
Revenue	$975.0M	↑ 11.9%
Net Income	$120.7M	↑ 4.14%
Net Profit Margin	12.38%	↓ 0.92%

	Q4 FY23	Q/Q Change
Revenue	$1.0B	↑ 6.1%
Net Income	$256.3M	↑ 112.34%
Net Profit Margin	24.78%	↑ 12.4%

	Q1 FY24	Q/Q Change
Revenue	$921.0M	↓ 10.97%
Net Income	$146.4M	↓ 42.88%
Net Profit Margin	15.9%	↓ 8.88%

	Q2 FY24	Q/Q Change
Revenue	$1.0B	↑ 9.04%
Net Income	$143.5M	↓ 1.98%
Net Profit Margin	14.29%	↓ 1.61%

	Q3 FY24	Q/Q Change
Revenue	$994.2M	↓ 1.01%
Net Income	$134.6M	↓ 6.2%
Net Profit Margin	13.54%	↓ 0.75%

	FY18	Y/Y Change
Total Assets	$1.9B	↑ 111.92%
Total Liabilities	$1.3B	↑ 158.45%

	FY19	Y/Y Change
Total Assets	$2.4B	↑ 25.0%
Total Liabilities	$1.5B	↑ 20.73%

	FY20	Y/Y Change
Total Assets	$4.3B	↑ 79.14%
Total Liabilities	$2.5B	↑ 62.92%

	FY21	Y/Y Change
Total Assets	$4.9B	↑ 13.36%
Total Liabilities	$2.6B	↑ 6.01%

	FY22	Y/Y Change
Total Assets	$5.4B	↑ 10.86%
Total Liabilities	$3.3B	↑ 24.8%

	FY23	Y/Y Change
Total Assets	$6.3B	↑ 16.19%
Total Liabilities	$4.2B	↑ 28.71%

	Q2 FY23	Q/Q Change
Total Assets	$6.8B	↑ 23.66%
Total Liabilities	$4.7B	↑ 43.78%

	Q3 FY23	Q/Q Change
Total Assets	$6.6B	↓ 3.29%
Total Liabilities	$4.3B	↓ 8.3%

	Q4 FY23	Q/Q Change
Total Assets	$6.3B	↓ 5.03%
Total Liabilities	$4.2B	↓ 3.06%

	Q1 FY24	Q/Q Change
Total Assets	$6.5B	↑ 3.48%
Total Liabilities	$4.2B	↑ 0.94%

	Q2 FY24	Q/Q Change
Total Assets	$6.8B	↑ 4.89%
Total Liabilities	$4.4B	↑ 3.06%

	Q3 FY24	Q/Q Change
Total Assets	$6.4B	↓ 6.55%
Total Liabilities	$4.4B	↑ 0.23%

	FY18	Y/Y Change
Operating Cash Flow	$123.2M	↑ 33.91%
Investing Cash Flow	$-139.8M	↓ 3.19%
Financing Cash Flow	$710.4M	↑ 78.0%

	FY19	Y/Y Change
Operating Cash Flow	$314.5M	↑ 155.28%
Investing Cash Flow	$-1.0B	↑ 626.18%
Financing Cash Flow	$10.7M	↓ 98.49%

	FY20	Y/Y Change
Operating Cash Flow	$475.6M	↑ 51.22%
Investing Cash Flow	$-1.0B	↑ 0.28%
Financing Cash Flow	$912.1M	↑ 8424.3%

	FY21	Y/Y Change
Operating Cash Flow	$442.5M	↓ 6.96%
Investing Cash Flow	$-216.1M	↓ 78.77%
Financing Cash Flow	$10.4M	↓ 98.86%

	FY22	Y/Y Change
Operating Cash Flow	$669.5M	↑ 51.3%
Investing Cash Flow	$-521.5M	↑ 141.32%
Financing Cash Flow	$-552.5M	↓ 5412.5%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$190.3M	↑ 22.46%
Investing Cash Flow	$-555.9M	↑ 197.75%
Financing Cash Flow	$939.5M	↑ 8288.39%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$269.2M	↑ 41.46%
Investing Cash Flow	$-179.5M	↓ 67.71%
Financing Cash Flow	$-637.4M	↓ 167.84%

Dexcom, Inc. Technicals Summary

Sell

Neutral

Buy

Dexcom, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Dexcom, Inc. Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Dexcom, Inc.	14.94%	-31.21%	-32.75%	-39.51%	43.55%
Stryker Corporation	5.35%	11.44%	35.35%	53.15%	94.43%
Boston Scientific Corp.	5.72%	18.8%	64.96%	122.19%	106.89%
Edwards Lifesciences Corp.	5.76%	-19.56%	1.5%	-37.0%	-9.69%
Abbott Laboratories	-0.78%	12.03%	11.31%	-11.82%	39.28%
Medtronic Plc	-3.5%	5.1%	9.49%	-21.5%	-22.13%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Dexcom, Inc.	48.07	48.07	1.22	1.71	0.32	0.06	NA	5.07
Stryker Corporation	42.03	42.03	2.74	12.06	0.19	0.07	0.01	52.86
Boston Scientific Corp.	74.93	74.93	1.64	2.46	0.09	0.05	NA	14.05
Edwards Lifesciences Corp.	27.55	27.55	6.52	2.53	0.19	0.11	NA	16.18
Abbott Laboratories	36.1	36.1	2.31	4.68	0.15	0.06	0.02	22.94
Medtronic Plc	26.38	26.38	1.56	5.2	0.08	0.04	0.03	38.29

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Dexcom, Inc.	Buy	$31.0B	43.55%	48.07	17.22%
Stryker Corporation	Buy	$149.5B	94.43%	42.03	16.34%
Boston Scientific Corp.	Buy	$133.7B	106.89%	74.93	11.26%
Edwards Lifesciences Corp.	Buy	$42.5B	-9.69%	27.55	65.86%
Abbott Laboratories	Buy	$206.3B	39.28%	36.1	13.99%
Medtronic Plc	Buy	$110.6B	-22.13%	26.38	12.06%

About Dexcom, Inc.

founded in 1999, dexcom, inc provides continuous glucose monitoring technology to help patients and their clinicians better manage diabetes. since our inception, we have focused on better outcomes for patients, caregivers, and clinicians by delivering solutions for people with diabetes — while empowering our community to take control of diabetes.

Organization	Dexcom, Inc.
Employees	9500
CEO	Mr. Kevin Ronald Sayer
Industry	Health Technology

Management People of Dexcom, Inc.

Name	Title
Mr. Kevin Ronald Sayer	Executive Chairman, CEO & President
Mr. Jereme M. Sylvain CPA	Executive VP, CFO & Chief Accounting Officer
Mr. Jacob Steven Leach	Executive VP & COO
Mr. Michael Jon Brown	Executive VP & Chief Legal Officer
Ms. Teri Lawver	Executive VP & Chief Commercial Officer
Mr. Girish Naganathan	Executive VP & CTO
Mr. Sean Christensen	Director of Corporate Affairs & Head of Investor Relations
Mr. Matthew Dolan	Executive Vice President of Strategy, Corporate Development & Dexcom Labs
Ms. Leverne Marsh	Executive Vice President of Marketing
Ms. Sadie M. Stern	Executive VP & Chief Human Resources Officer

Important FAQs about investing in Dexcom, Inc. from India :

What is Dexcom, Inc. share price today?

Dexcom, Inc. (DXCM) share price today is $81.01.

Can Indians buy Dexcom, Inc. shares?

Yes, Indians can invest in the Dexcom, Inc. (DXCM) from India.

With INDmoney, you can buy Dexcom, Inc. at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Dexcom, Inc. at zero transaction cost.

How can I buy Dexcom, Inc. shares from India?

It is very easy to buy Dexcom, Inc. from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Dexcom, Inc. be purchased?

Yes, you can buy fractional shares of Dexcom, Inc. with INDmoney app.

What are the documents required to start investing in Dexcom, Inc. stocks?

To start investing in Dexcom, Inc., You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.